Press Releases

Date   Headline
Jul 21, 2015 Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3
Jul 16, 2015 Cleveland BioLabs Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement
Jul 13, 2015 Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation
Jul 10, 2015 Cleveland BioLabs Announces Board Appointments
Jul 09, 2015 Cleveland BioLabs Closes Private Placement With Strategic Investor for $25 Million Equity Financing
Jun 25, 2015 Cleveland BioLabs Enters Into Private Placement Agreement With Strategic Investor for $25 Million Equity Financing
Jun 15, 2015 Cleveland BioLabs Submits Pre-EUA Dossier for Entolimod to FDA
Jun 01, 2015 Cleveland BioLabs Releases Entolimod Phase 1 Study Findings at ASCO
May 06, 2015 Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress
May 05, 2015 Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
Apr 30, 2015 Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6
Apr 29, 2015 Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture
Apr 27, 2015 Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod
Apr 22, 2015 Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
Apr 14, 2015 Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue